Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$103.14 USD

103.14
5,076,184

+0.18 (0.17%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $103.11 -0.03 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

DexCom's (DXCM) G7 CGM System Now Connects to Apple Watch

by Zacks Equity Research

DexCom (DXCM) announces the direct connectivity of its G7 CGM system to Apple Watch for users in the United States, the UK, and Ireland.

Zacks Equity Research

BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite

by Zacks Equity Research

BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.

Zacks Equity Research

Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Zacks Equity Research

Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System

by Zacks Equity Research

Stryker (SYK) announces the launch of LIFEPAK 35 monitor/defibrillator, which is likely to aid emergency responders to reduce cognitive load during demanding situations by improving workflow.

Zacks Equity Research

Stryker's (SYK) Acquisition of Artelon Set to Expand Its Market

by Zacks Equity Research

Stryker (SYK) announces the signing of the definitive agreement to acquire a privately held company, Artelon, to strengthen its foothold in the soft tissue fixation market.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Zacks Equity Research

HealthEquity (HQY) Q1 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2025.

Zacks Equity Research

Inari's (NARI) Expanding Product Portfolio Offsets Competition

by Zacks Equity Research

Inari's (NARI) VTE products are driving its top line on the back of robust adoption. The company is expanding in additional indications to fuel growth and fight competition.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Three Reasons to Retain BD (BDX) Stock in Your Portfolio Now

by Zacks Equity Research

BD's (BDX) robust product portfolio raises optimism about the stock.

Zacks Equity Research

Patterson Companies' (PDCO) New Launch to Boost Patient Service

by Zacks Equity Research

Patterson Companies' (PDCO) Patterson CarePay+ is likely to improve overall patient care and streamline practice operations.

Zacks Equity Research

ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment

by Zacks Equity Research

ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.

Zacks Equity Research

Boston Scientific (BSX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

In the latest trading session, Boston Scientific (BSX) closed at $75.57, marking a +0.76% move from the previous day.

Zacks Equity Research

Envista (NVST) Down 4.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M

by Zacks Equity Research

Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.

Zacks Equity Research

DaVita (DVA) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in kidney care.

Zacks Equity Research

Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both segments.

Zacks Equity Research

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Zacks Equity Research

Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe

by Zacks Equity Research

Stryker (SYK) announces plan to launch its Gamma4 Hip Fracture Nailing System in Europe. It completes initial surgeries successfully.

Zacks Equity Research

Reasons Why You Should Retain Avantor (AVTR) Stock for Now

by Zacks Equity Research

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

Zacks Equity Research

Stryker (SYK) Issues Safety Notice for Its Total Knee System

by Zacks Equity Research

Stryker (SYK) issues urgent field safety notice for the Mako Total Knee systems, the application software of which generated software error codes. The company also shares risk mitigation steps.

Zacks Equity Research

Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Zacks Equity Research

Intuitive Surgical (ISRG) Stock Gains 20% YTD: Here's Why

by Zacks Equity Research

Intuitive Surgical (ISRG) shares gain on the back of growth in the da Vinci treatment volume and raised procedure prices.

Zacks Equity Research

HAE or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HAE vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

ResMed (RMD) Up 16.3% Since Last Earnings: Will it Continue?

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) led by strong growth in the U.S. mask and accessories business and its cloud-connected platforms.